JP2011525191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525191A5 JP2011525191A5 JP2011514851A JP2011514851A JP2011525191A5 JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5 JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable composition
- antigen
- cells
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 241000186216 Corynebacterium Species 0.000 claims 1
- 241001464975 Cutibacterium granulosum Species 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7458208P | 2008-06-20 | 2008-06-20 | |
| US61/074,582 | 2008-06-20 | ||
| PCT/US2009/047987 WO2009155535A2 (en) | 2008-06-20 | 2009-06-19 | Compositions, methods and kits for eliciting an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Division JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525191A JP2011525191A (ja) | 2011-09-15 |
| JP2011525191A5 true JP2011525191A5 (https=) | 2012-08-09 |
Family
ID=41434717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514851A Pending JP2011525191A (ja) | 2008-06-20 | 2009-06-19 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (12) | US8425898B2 (https=) |
| EP (4) | EP3156069B8 (https=) |
| JP (3) | JP2011525191A (https=) |
| CN (1) | CN102123732A (https=) |
| AU (1) | AU2009259923B2 (https=) |
| CA (1) | CA2728739C (https=) |
| DK (1) | DK3156069T3 (https=) |
| WO (1) | WO2009155535A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| EP3156069B8 (en) * | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| EP3238782A3 (en) * | 2010-04-06 | 2018-01-03 | ExoCyte Therapeutics Pte, LTD | Methods of treating cancer |
| EP2697248B1 (en) * | 2011-04-15 | 2020-03-11 | Nauclér, Cecilia | Genetic variant of cytomegalovirus (cmv) |
| CN102363818B (zh) * | 2011-06-28 | 2013-01-02 | 同昕生物技术（北京）有限公司 | 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒 |
| CA2885145A1 (en) * | 2012-10-30 | 2014-05-08 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| WO2014127148A1 (en) * | 2013-02-14 | 2014-08-21 | The J. David Gladstone Institutes | Compositions and methods of use thereof for identifying anti-viral agents |
| EP3049092A4 (en) * | 2013-09-24 | 2017-09-06 | Duke University | Compositions, methods and kits for eliciting an immune response |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US9974848B2 (en) | 2013-11-14 | 2018-05-22 | Duke University | Tetanus toxoid and CCL3 improve DC vaccines |
| EP3074770B1 (en) * | 2013-11-26 | 2020-04-29 | Duke University | Immune monitoring to predict and prevent infection |
| AU2015343239B2 (en) | 2014-11-05 | 2021-06-03 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| WO2016154620A1 (en) * | 2015-03-26 | 2016-09-29 | University Of Houston System | Integrated functional and molecular profiling of cells |
| WO2016209816A1 (en) | 2015-06-26 | 2016-12-29 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| US11464839B2 (en) | 2015-12-04 | 2022-10-11 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different MHC molecules |
| SG11201805186VA (en) | 2016-01-20 | 2018-07-30 | Fate Therapeutics Inc | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| PL3429618T3 (pl) | 2016-03-16 | 2024-07-01 | Amal Therapeutics Sa | Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| AU2017330379B2 (en) | 2016-09-23 | 2023-07-13 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory T cells |
| EP3528821A4 (en) * | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| EP3548049A4 (en) * | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| US12338458B2 (en) | 2017-05-25 | 2025-06-24 | Memorial Sloan Kettering Cancer Center | Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy |
| US11925663B2 (en) | 2017-10-23 | 2024-03-12 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| KR20250044945A (ko) * | 2017-11-06 | 2025-04-01 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 기존의 미생물 면역을 활용한 암 치료 |
| JP2021512950A (ja) | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． | 新規なワクチンの免疫補助剤 |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| BR112021024157A2 (pt) * | 2019-05-31 | 2022-04-26 | Variation Biotechnologies Inc | Composições imunoterapêuticas para tratamento de glioblastoma multiforme |
| WO2021048081A1 (en) * | 2019-09-09 | 2021-03-18 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
| JP2023078487A (ja) * | 2020-04-08 | 2023-06-07 | アステラス製薬株式会社 | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 |
| JP7352040B2 (ja) * | 2020-05-22 | 2023-09-27 | フィロジェン エッセ．ピー．アー． | 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法 |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| EP4192494A4 (en) * | 2020-08-06 | 2024-11-13 | La Jolla Institute for Immunology | Methods for treating and preventing cytomegalovirus infection |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| GB2603166A (en) * | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
| WO2022192323A1 (en) * | 2021-03-09 | 2022-09-15 | Board Of Regents, The University Of Texas System | Low intensity ultrasound combination cancer therapies |
| CN117257925B (zh) * | 2023-09-20 | 2024-05-28 | 青岛大学 | 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US6207161B1 (en) | 1986-07-16 | 2001-03-27 | City Of Hope | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides |
| US4906564A (en) | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
| DE69132311T2 (de) | 1990-09-25 | 2000-12-14 | Cantab Pharmaceuticals Research Ltd., Cambridge | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| JPH08506325A (ja) * | 1993-01-28 | 1996-07-09 | サンド ファーマスーティカル コーポレーション | サイトメガロウイルスに対するヒトモノクローナル抗体 |
| JPH08507784A (ja) | 1993-03-19 | 1996-08-20 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウイルス・ワクチン |
| EP0914441A2 (en) * | 1996-04-23 | 1999-05-12 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6156317A (en) | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6503503B1 (en) | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6291446B1 (en) | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| WO2000011950A1 (en) | 1998-08-31 | 2000-03-09 | Oregon Health Science University | Prevention of cell migration initiation with cmv us28 receptor antagonists |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6350451B1 (en) | 1999-06-25 | 2002-02-26 | The Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
| US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| WO2001066138A2 (en) | 2000-03-07 | 2001-09-13 | U.S. Army Medical Research Institute Of Infectious Diseases | Dna vaccines against poxviruses |
| EP1265916B1 (en) | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| EP1146119A1 (en) | 2000-04-12 | 2001-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes |
| WO2002018954A2 (en) * | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
| US20040241140A1 (en) | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| AU2003268355A1 (en) | 2002-09-03 | 2004-03-29 | The Uab Research Foundation | Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells |
| US7740871B2 (en) | 2002-09-19 | 2010-06-22 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| ATE353954T1 (de) | 2002-10-11 | 2007-03-15 | Sentoclone Therapeutics Ab | Immuntherapie für krebs |
| AU2003296439B2 (en) | 2002-12-10 | 2009-05-07 | Argos Therapeutics, Inc. | In situ maturation of dendritic cells |
| DK2311848T3 (da) | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| US7163685B2 (en) | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| US20050232933A1 (en) | 2003-09-30 | 2005-10-20 | Zaia John A | CMV-IE1 peptides and method of use |
| US7976845B2 (en) * | 2004-11-29 | 2011-07-12 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| US20100111992A1 (en) * | 2006-05-01 | 2010-05-06 | The Regents Of The University Of California | Cytomegalovirus peptides and methods of use thereof |
| CA2700436C (en) | 2006-09-28 | 2017-04-18 | John S. Yu | Cancer vaccines and vaccination methods |
| WO2009021150A2 (en) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| EP3156069B8 (en) * | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| WO2010002983A2 (en) | 2008-07-03 | 2010-01-07 | Duke University | Composition and methods for eliciting an immune response |
| US9974848B2 (en) * | 2013-11-14 | 2018-05-22 | Duke University | Tetanus toxoid and CCL3 improve DC vaccines |
-
2009
- 2009-06-19 EP EP16184921.1A patent/EP3156069B8/en active Active
- 2009-06-19 US US12/488,176 patent/US8425898B2/en active Active
- 2009-06-19 CA CA2728739A patent/CA2728739C/en active Active
- 2009-06-19 AU AU2009259923A patent/AU2009259923B2/en active Active
- 2009-06-19 EP EP22202748.4A patent/EP4218806A1/en not_active Withdrawn
- 2009-06-19 CN CN2009801288723A patent/CN102123732A/zh active Pending
- 2009-06-19 EP EP20181935.6A patent/EP3766517B1/en active Active
- 2009-06-19 WO PCT/US2009/047987 patent/WO2009155535A2/en not_active Ceased
- 2009-06-19 DK DK16184921.1T patent/DK3156069T3/da active
- 2009-06-19 EP EP09767844.5A patent/EP2303319B1/en active Active
- 2009-06-19 JP JP2011514851A patent/JP2011525191A/ja active Pending
-
2013
- 2013-01-23 US US13/748,096 patent/US9011835B2/en active Active
-
2015
- 2015-01-30 JP JP2015016782A patent/JP2015134767A/ja active Pending
- 2015-04-08 US US14/681,534 patent/US9764026B2/en active Active
-
2016
- 2016-12-22 JP JP2016249706A patent/JP6342982B2/ja active Active
-
2017
- 2017-08-14 US US15/676,330 patent/US10632190B2/en not_active Expired - Fee Related
-
2020
- 2020-03-18 US US16/822,354 patent/US11389530B2/en active Active
- 2020-07-22 US US16/935,813 patent/US11351248B2/en active Active
- 2020-07-23 US US16/937,171 patent/US11364295B2/en active Active
- 2020-07-24 US US16/937,801 patent/US11376322B2/en active Active
-
2022
- 2022-05-06 US US17/738,576 patent/US20220370602A1/en not_active Abandoned
- 2022-05-17 US US17/746,329 patent/US20220387582A1/en not_active Abandoned
- 2022-05-31 US US17/828,554 patent/US12070496B2/en active Active
- 2022-06-15 US US17/841,140 patent/US20220401552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525191A5 (https=) | ||
| Wu et al. | The mucosal immune system in the oral cavity—an orchestra of T cell diversity | |
| JP2023052777A5 (https=) | ||
| Ray et al. | Regulatory T cells in many flavors control asthma | |
| Durward et al. | Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis | |
| McKinstry et al. | The potential of CD4 T‐cell memory | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| JP2014507482A5 (https=) | ||
| JP2012021028A5 (https=) | ||
| GB2434367A (en) | Improved vaccines | |
| JP2016513115A5 (https=) | ||
| EP2385059A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| WO2012116225A3 (en) | Muc1 based glycolipopeptide vaccine with adjuvant | |
| Dong et al. | Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection | |
| WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
| WO2016038625A3 (en) | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it | |
| Wei et al. | Kinetics of Th 17‐related cytokine expression in experimentally induced rat periapical lesions | |
| JP2015526469A5 (https=) | ||
| JP2018501322A5 (https=) | ||
| JP2019526270A5 (https=) | ||
| WO2009029272A3 (en) | Epitope vaccine for prevention and reversion of ad pathology | |
| JP2013504600A5 (https=) | ||
| Aggarwal et al. | Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice | |
| RU2013143741A (ru) | Терапевтическая вакцина против рака | |
| WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy |